(Q34513318)

English

The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic rena

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic rena (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

object named as

Sandy Tubeuf

7

0 references

object named as

Helen Howard

4

0 references

11

object named as

Peter J Selby

0 references

13

object named as

Julia Brown

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Fiona J Collinson

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Walter M Gregory

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Chris McCabe

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Catherine Lowe

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

DrBarbara Potrata

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Pat Hanlon

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lucy McParland

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

T Wah

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jenny Hewison

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Janet Brown

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

14 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

full work available at URL

http://eprints.whiterose.ac.uk/75297/

content deliverer

White Rose Research Online

object has role

published version

copyright license

Creative Commons Attribution 2.0 Generic

0 references

https://doi.org/10.1186/1471-2407-12-598

copyright license

Creative Commons Attribution 2.0 Generic

object has role

published version

0 references

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

598

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Sunitinib rechallenge in metastatic renal cell carcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Tyrosine kinase blockers: new hope for successful cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Relation between duration and intensity of first exercise and "warm up" in ischaemic heart disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Adjusting survival curves for imbalances in prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

7 July 2018

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-598

21 January 2018

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-598

21 January 2018

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-598

21 January 2018

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-598

21 January 2018

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-598

21 January 2018

It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

27 October 2018

Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

27 October 2018

Expected value of sample information calculations in medical decision modeling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583710

27 October 2018

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23241439

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23241439

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-12-598

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

10.1186/1471-2407-12-598

0 references

0 references

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

2-s2.0-84870898413

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34513318&oldid=2196727721"